An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance i…
VERDICT
The label
Markup
read at $366.81
Praxis Precision Medicines Inc holds its Markup at $366.81.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-14
Phase
Markup
Quantitative state
Elevated stress, defensive posture warranted, held for 3 days
Price
$366.81
Valuation
N/A trailing · -39.00 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.78
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$366.81
N/A P/E · -39.00 fwd
Our fair value
$550.00
50% discount
Analyst target (avg)
$550.00
+50% to current
Target low $188.00Analyst target rangeTarget high $1,201.00
▲ current $366.81 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$366.81
you are here
Conservative
$188.00
-49%
Analyst avg
$550.00
+50%
Our fair value
$550.00
+50%
Analyst high
$1,201.00
+227%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Profit margin
0.00%
Debt to equity
0.08
Analyst consensus
Strong Buy · 19 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its interest-bearing securities. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 0.0% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashInterest-bearing cash and securities are 34.8% of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is 38.1% of assets, under the 49% limit.Pass
Revenue purity of revenue comes from non-compliant sources, over the 5% line.Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Clinical bets on brain drugs carry heavy odds
A company chasing fixes for scrambled signals in the brain can sound like the next medical leap. Praxis is still years from any revenue, posts zero profit margins and runs a negative return on equity of 35 percent, so the numbers show a business that burns cash rather than compounds it.
Analysts set a median target at 550 dollars against the current 314 dollar price, yet our opportunity rating sits at none. The weak moat leaves any future success open to fast copying, and a forward price to earnings ratio of negative 32.6 times simply reflects ongoing losses rather than hidden value.
High failure rates in central nervous system trials remain the real risk here, even after clearing the ethical screen. One late-stage setback could wipe out the apparent discount in a single announcement. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in PRAX's space worth a look
Screened names in the same industry · explore each on its own page.
TRADER
The trader read · the latest dated commentary
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 13% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 424%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (18 analysts) rates it strong buy, with a mean price target of $618. Entered 2026-08-09 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-08-09Markup · changed$307.75+15.4%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 13% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 424%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (18 analysts) rates it strong buy, with a mean price target of $618.
2026-07-18Distribution$266.58+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 13% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 424%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (18 analysts) rates it strong buy, with a mean price target of $618.
2026-07-03Distribution$266.58+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Distribution$266.58Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$331.81
-27.6%
·
$724
-27.6%
2 months
$316.14
-24.0%
·
$760
-24.0%
3 months
$303.37
-20.8%
·
$792
-20.8%
6 months
$267.28
-10.2%
·
$899
-10.2%
1 year
$45.85
+423.8%
·
$5,238
+423.8%
2 years
$40.56
+492.1%
·
$5,921
+492.1%
3 years
$14.82
+1,520.5%
·
$16,205
+1,520.5%
5 years
$301.05
-20.2%
·
$798
-20.2%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever PRAX does next, these words stay.
Praxis Precision Medicines Inc · PRAX · Markup · $366.81
Recorded 2026-08-14 · before the outcome · scored mechanically
